Genome alterations found here suggest that the losses of TSs as PTEN, LKB1 and PDCD4 as well as the gain of the oncogene P70S6K might converge toward an increased oncogenic activity of PI3K/AKT/mTORC1 signaling and that many members might represent novel therapeutic targets to treat SS (Fig. 6a) [33]. The gene discussed is PTEN; the disease is synovial sarcoma.